INSERM UMR861, I-Stem, AFM, Corbeil-Essonnes, France.
UEVE UMR861, I-Stem, AFM, Corbeil-Essonnes, France.
Adv Exp Med Biol. 2018;1074:625-632. doi: 10.1007/978-3-319-75402-4_76.
Recent clinical trials based on human pluripotent stem cell-derived retinal pigment epithelium cells (hPSC-RPE cells) were clearly a success regarding safety outcomes. However the delivery strategy of a cell suspension, while being a smart implementation of a cell therapy, might not be sufficient to achieve the best results. More complex reconstructed tissue formulations are required, both to improve functionality and to target pathological conditions with altered Bruch's membrane like age-related macular degeneration (AMD). Herein, we describe the various options regarding the stem cell source choices and the different strategies elaborated in the recent years to develop engineered RPE sheets amenable for regenerative therapies.
最近基于人多能干细胞来源的视网膜色素上皮细胞（hPSC-RPE 细胞）的临床试验在安全性方面显然取得了成功。然而，细胞悬浮液的输送策略虽然是细胞治疗的一种明智的实施方式，但可能不足以达到最佳效果。需要更复杂的重建组织配方，既要提高功能，又要针对像年龄相关性黄斑变性（AMD）这样的病理性改变的布鲁赫膜进行靶向治疗。本文描述了关于干细胞来源选择的各种选择以及近年来为开发适合再生疗法的工程化 RPE 片而精心设计的不同策略。
